.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Farmers Insurance
Moodys
Mallinckrodt
Merck
Baxter
Citi
Harvard Business School
Chubb
Argus Health

Generated: June 29, 2017

DrugPatentWatch Database Preview

Sorafenib tosylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for sorafenib tosylate and what is the scope of sorafenib tosylate freedom to operate?

Sorafenib tosylate
is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. There are eight patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Sorafenib tosylate has one hundred and fifty-four patent family members in fifty-four countries.

There are ten drug master file entries for sorafenib tosylate. One supplier is listed for this compound.

Summary for Generic Name: sorafenib tosylate

Tradenames:1
Patents:8
Applicants:1
NDAs:1
Drug Master File Entries: see list10
Suppliers / Packagers: see list1
Bulk Api Vendors: see list72
Clinical Trials: see list680
Therapeutic Class:Antineoplastics
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:sorafenib tosylate at DailyMed

Pharmacology for Ingredient: sorafenib tosylate

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare
NEXAVAR
sorafenib tosylate
TABLET;ORAL021923-001Dec 20, 2005RXYesYes7,897,623► SubscribeY ► Subscribe
Bayer Hlthcare
NEXAVAR
sorafenib tosylate
TABLET;ORAL021923-001Dec 20, 2005RXYesYes8,618,141► Subscribe ► Subscribe
Bayer Hlthcare
NEXAVAR
sorafenib tosylate
TABLET;ORAL021923-001Dec 20, 2005RXYesYes7,235,576► SubscribeYY ► Subscribe
Bayer Hlthcare
NEXAVAR
sorafenib tosylate
TABLET;ORAL021923-001Dec 20, 2005RXYesYes8,124,630► Subscribe ► Subscribe
Bayer Hlthcare
NEXAVAR
sorafenib tosylate
TABLET;ORAL021923-001Dec 20, 2005RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: sorafenib tosylate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,528,255Hydroxy, .omega.-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors► Subscribe
8,242,147Aryl ureas with angiogenisis inhibiting activity► Subscribe
7,928,239Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas► Subscribe
7,838,541Aryl ureas with angiogenesis inhibiting activity► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: sorafenib tosylate

Country Document Number Estimated Expiration
Denmark1797038► Subscribe
Panama8489701► Subscribe
Slovakia9882001► Subscribe
Turkey200102020► Subscribe
Norway20013463► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SORAFENIB TOSYLATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2006 008, C 1140840Lithuania► SubscribePRODUCT NAME: SORAFENIBAS IR FARMACINIU PO?I?RIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
2006008Lithuania► SubscribePRODUCT NAME: SORAFENIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
2006008,C1140840Lithuania► SubscribePRODUCT NAME: SORAFENIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
0242Netherlands► Subscribe
2006000059Germany► SubscribePRODUCT NAME: SORAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Healthtrust
Chubb
Johnson and Johnson
Deloitte
US Army
Argus Health
Colorcon
Fuji
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot